BioRestorative Therapies is a life sciences company that develops regenerative medicine treatments primarily using adult stem cells. Their core developmental programs target disc/spine disease and metabolic disorders with lead cell therapy candidate BRTX-100, and a preclinical stage Thermostem respectively. The company has research and development agreements with Rohto Pharmaceutical, Pfizer, and the University of Pennsylvania, and is based in Melville, New York.